Retrospective Analysis of Skin Toxicity in Patients under Anti-EGFR Tyrosine Kinase Inhibitors: Our Experience in Lung Cancer | Zendy

Maria Carmela Annunziata | Zendy; Maria Ferrillo | Zendy; Eleonora Cinelli | Zendy; Luigia Panariello | Zendy; Danilo Rocco | Zendy; Gabriella Fabbrocini | Zendy

Open Access

Retrospective Analysis of Skin Toxicity in Patients under Anti-EGFR Tyrosine Kinase Inhibitors: Our Experience in Lung Cancer

Author(s) -

Maria Carmela Annunziata,

Maria Ferrillo,

Eleonora Cinelli,

Luigia Panariello,

Danilo Rocco,

Gabriella Fabbrocini

Publication year - 2019

Publication title -

open access macedonian journal of medical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.288

H-Index - 17

ISSN - 1857-9655

DOI - 10.3889/oamjms.2019.170

Subject(s) - medicine , erlotinib , afatinib , rash , lung cancer , dermatology , skin cancer , mucocutaneous zone , gefitinib , cancer , papulopustular , adverse effect , epidermal growth factor receptor , disease , rosacea , acne

Tyrosine kinase inhibitors (TKIs) have been introduced for the treatment of lung cancer, improving progression-free survival, objective response rate, and quality of life. However, TKIs can lead to cutaneous toxicities, including papulopustular rash, xerosis, paronychia with/without pyogenic granulomas, scalp disorders, facial hair and/or eyelash growth.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research